

Teriparatide acetate hydrate

Cat. No.:	HY-P0059A
CAS No.:	99294-94-7
Molecular Formula:	$C_{181}H_{291}N_{55}O_{51}S_2.C_2H_4O_2.xH_2O$
Sequence Shortening:	SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF (acetate salt, hydrate)
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PTH1 receptor agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research ^[1] .								
In Vivo	<p>Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) (20 µg/kg, i.h.; daily, for 4 weeks; female New Zealand white rabbits) increases the cortical thickness and porosity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td><td>Female New Zealand white rabbits^[1]</td></tr> <tr> <td>Dosage:</td><td>20 µg/kg</td></tr> <tr> <td>Administration:</td><td>Subcutaneous injection; daily, for 4 weeks</td></tr> <tr> <td>Result:</td><td>Increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD).</td></tr> </table>	Animal Model:	Female New Zealand white rabbits ^[1]	Dosage:	20 µg/kg	Administration:	Subcutaneous injection; daily, for 4 weeks	Result:	Increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD).
Animal Model:	Female New Zealand white rabbits ^[1]								
Dosage:	20 µg/kg								
Administration:	Subcutaneous injection; daily, for 4 weeks								
Result:	Increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD).								

CUSTOMER VALIDATION

- Nat Commun. 2023 May 31;14(1):3159.
- Biomed Pharmacother. 2019 Feb 18;112:108578.
- J Orthop Translat. 2022 Dec 7;38:241-255.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Iwamoto J, et, al. Influence of Teriparatide and Ibandronate on Cortical Bone in New Zealand White Rabbits: A HR-QCT Study. Calcif Tissue Int. 2016

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA